Lawrence Evans Email & Phone Number

Seattle, Washington, US

• 𝐀𝐋𝐏𝐍-101 (𝐚𝐜𝐚𝐳𝐢𝐜𝐨𝐥𝐜𝐞𝐩𝐭, 𝐝𝐮𝐚𝐥 𝐈𝐂𝐎𝐒 𝐚𝐧𝐝 𝐂𝐃28 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫) 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭
• Primary role in ALPN-101 drug development. Contributions include: lead identification; development of T follicular helper and germinal-center B cell reaction assay to demonstrate importance of inhibition of both ICOS.
• Determined the ability of ALPN-101 to modulate cytokine response and/or gene expression from RA, PsA, SLE, SjS, MS, IBD and ILD patient samples; generated a robust data set for corporate business development /.
• Phase 2 clinical trial in SLE is currently enrolling patients (partnership with Abbvie Inc.) 𝐀𝐋𝐏𝐍-303 (𝐩𝐨𝐯𝐞𝐭𝐚𝐜𝐢𝐜𝐞𝐩𝐭, 𝐝𝐮𝐚𝐥 𝐀𝐏𝐑𝐈𝐋 𝐚𝐧𝐝 𝐁𝐀𝐅𝐅 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫) 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭
• Primary role in ALPN-303 drug development. Contributions include: lead identification; development of a primary B cell assay to demonstrate impact of both APRIL and BAFF inhibition; IND-enabling studies.
• Phase I healthy volunteer study completed. Clinical trials for autoimmune kidney diseases and autoimmune cytopenias initiated.𝐏𝐫𝐨𝐣𝐞𝐜𝐭 𝐓𝐞𝐚𝐦 𝐋𝐞𝐚𝐝 𝐨𝐟 𝐭𝐡𝐞 𝐅𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐆𝐫𝐨𝐮𝐩

Thousand Oaks, CA, US

• Highly engaged and consistent top performer while working in two interdisciplinary departments.
• Project leader for discovery programs for inflammation and cancer immunotherapy:
• Championed an adaptive Chimeric Antigen Receptor (CAR) program for cancer immunotherapy
• Key member of a comprehensive immuno-oncology task force focused on Bi-specific T-cell Engagers (BiTEs), Oncolytic viruses, CARs, checkpoint and co-stimulation targets
• Researched an antibody-drug conjugate targeting T-cells for inflammatory diseases
• Focused research on Idiopathic Pulmonary Fibrosis (IPF) and Scleroderma:

Thousand Oaks, CA, US

• Provided data and study reports to support IND filing of AMG80 (anti-CSF1R antibody), including mechanism of action studies.
• Characterized tumor-associated macrophage and immune cell infiltrates from a variety of syngeneic and xenograft tumor models to monitor tumor immune microenvironment
• Discovered a role for myeloid-derived suppressor cells in promoting tumor metastasis
• In vivo lead for therapeutic antibody program specific for costimulatory TNF receptor superfamily member.
• Identified lead clinical antibody and developed a novel in vivo assay to support mechanism of action studies. Perform internal studies (including PK/PD, toxicology) and coordinated studies with CROs

• Focused research and development of Toll-like receptor agonists and antagonists for use as vaccine adjuvants and monotherapy applications:
• Developed a model to evaluate WT-1 leukemia vaccine (antigenicity, formulation, and delivery) and provided critical data and input from exploratory phase through to human clinical trial design
• Identified optimal formulations of TLR3, 4, 5, 7 and 9 individually or in combinations for induction of antigen-specific humoral and cellular responses.
• Developed in vivo and in vitro assays for several infectious disease and cancer antigens Evaluated numerous vaccine delivery techniques and technologies:
• Demonstrated improved delivery methods for DNA, viral, and protein based vaccines. Coordinated efforts between internal departments and external corporate and academic partners.

• Focused research on adoptive immunotherapy of genetically modified T-cells:
• Demonstrated expression and signaling of chimeric receptors in primary cells and celllines after improving transduction efficiencies
• Generated and characterized antigen specific murine and human CTLAssayed humoral immune responses to recombinant Adeno-Associated Viral (AAV) vectors and transgenes from various in vivo studies:
• Developed a high throughput assay to quantitate AAV neutralizing antibodies
• Developed and validated ELISAs to measure antibody responses to transgenes from murine, macaque, rabbit and human sera or BAL samples